Skip to main content
IBIO logo

iBio, Inc.

IBIONASDAQHealthcareBiotechnology

$0.71Today:- (-)1Y −38.27%

As of Oct 26, 2026 close

Market cap
$73.57M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$0.73$3.82
Volume (live)
-
Avg. volume (3M)
833.34K

iBio (IBIO) Income Statement

iBio reported revenue of $100.00K in fiscal 2026 (fiscal year ended Jun 30, 2026), down 75.0% from $400.00K a year earlier. iBio posted a net loss of $33.04M, compared with a net loss of $18.38M a year earlier. Gross margin was 100.0% and operating margin -30138.0%.

iBio Income Statement Analysis

Values in millions USD

Scroll to see more
iBio, Inc. income statement - Annual data in millions USD
BreakdownFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingJun 2026Jun 2025Jun 2024Jun 2023Jun 2022Jun 2021Sep 2020Jun 2019Jun 2018Jun 2017
Revenue & Gross Profit
Revenue0.100.400.230.001.882.371.642.020.440.39
Cost of Revenue0.000.000.000.003.791.460.700.000.000.00
Gross Profit0.100.400.230.00-1.910.910.942.020.440.39
Operating Expenses
Research & Development19.648.315.1910.339.839.993.575.473.994.12
Selling, General & Administrative10.6010.6911.6718.4517.9621.8911.3712.3310.6910.55
Operating Expenses30.2419.0016.8629.3427.7932.0214.9417.8114.6714.67
Operating Income-30.14-18.60-16.63-29.34-29.70-31.11-14.00-15.79-14.23-14.27
Other Income/Expense
Interest Income2.150.440.360.210.180.140.020.080.020.04
Interest Expense0.050.210.17-0.081.412.452.471.901.921.93
Other Income/Expense-5.000.451.190.030.187.90-2.44-1.81-1.88-1.87
Income
Income Before Tax-33.04-18.38-15.44-29.31-29.51-23.21-16.44-17.60-16.11-14.53
Income Tax Expense0.000.000.000.000.000.000.000.000.030.35
Net Income-33.04-18.38-24.91-65.01-50.39-23.21-16.44-17.59-16.11-14.53
Net Income - Continuous Operations-33.04-18.38-24.91-29.31-50.39-23.21-16.44-17.59-16.11-14.53
Net Income - Discontinued Operations---9.46-35.70-20.79-----
EBITDA-31.96-17.04-14.02-28.05-25.72-28.55-11.74-13.95-12.48-12.53
EBIT-32.99-18.17-16.63-28.78-29.51-31.11----
Depreciation & Amortization1.031.131.250.733.792.412.241.751.711.68
Earnings Per Share
Basic EPS--2.00-6.00-106.00-2889.00-60.00-305.00-472.00-770.00-800.00
Diluted EPS--2.00-6.00-106.00-2889.00-60.00-305.00-472.00-770.00-800.00
Basic Shares Outstanding104.0610.503.830.610.020.390.130.040.020.02
Diluted Shares Outstanding104.0610.503.830.610.020.390.130.040.020.02

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About iBio Financial Statements

What was iBio's revenue in fiscal 2026?

iBio reported revenue of $100.00K in fiscal 2026 (fiscal year ended Jun 30, 2026). That was down 75.0% from $400.00K a year earlier.

Is iBio profitable?

No. iBio reported a net loss of $33.04M in fiscal 2026. In fiscal 2025 it lost $18.38M.

What is iBio's operating margin?

iBio's operating income was −$30.14M on revenue of $100.00K in fiscal 2026, an operating margin of -30138.0%, compared with -4650.5% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition